VMX-C001

DRUG3 trials

Sponsors

VarmX B.V.

Conditions

Coagulation Disorder

Phase 1

Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects

CompletedNCT05152420

VarmX B.V.Coagulation Disorder

Start: 2021-10-29End: 2023-02-03Updated: 2023-06-02

Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant

CompletedNCT06372483

VarmX B.V.Coagulation Disorder

Start: 2024-02-21End: 2026-08-26Updated: 2026-09-09

Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin

CompletedNCT06517563

VarmX B.V.Coagulation Disorder

Start: 2024-08-14End: 2026-04-13Updated: 2026-05-11

Related Papers

Phase 1 Study of the Safety and Pharmacodynamics of a Single Dose of Vmx-C001 in Healthy Subjects with and without FXa Direct Oral Anticoagulants

Blood2024-11-05